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Clinical trial enrichmentDesigners of clinical trials for Alzheimer's disease (AD) and mild cognitive impairment (MCI) are actively
considering structural and functional neuroimaging, cerebrospinal ﬂuid and genetic biomarkers to reduce
the sample sizes needed to detect therapeutic effects. Genetic pre-selection, however, has been limited to
Apolipoprotein E (ApoE). Recently discovered polymorphisms in the CLU, CR1 and PICALM genes are also
moderate risk factors for AD; each affects lifetime AD risk by ~10–20%. Here, we tested the hypothesis that
pre-selecting subjects based on these variants along with ApoE genotype would further boost clinical trial
power, relative to considering ApoE alone, using an MRI-derived 2-year atrophy rate as our outcome mea-
sure. We ranked subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) based on their cumu-
lative risk from these four genes. We obtained sample size estimates in cohorts enriched in subjects with
greater aggregate genetic risk. Enriching for additional genetic biomarkers reduced the required sample
sizes by up to 50%, for MCI trials. Thus, AD drug trial enrichment with multiple genotypes may have potential
implications for the timeliness, cost, and power of trials.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Dementia is a devastating disease, with costs exceeding those of
cancer and heart disease (Hurd et al., 2013). There is a crucial need
for Alzheimer's disease treatments that go beyond merely alleviatingLaboratory of Neuro Imaging,
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nc. Open access under CC BY-NC-ND lisymptoms of this devastating disease. Powerful clinical trial designs
are vital to novel drug development. In recent years, multiple ap-
proaches using neuroimaging, biochemical and genetic biomarkers
have been proposed for enrichment of AD trials, i.e., reducing the
number of subjects needed to detect potential drug effects. By
enriching a sample in subjects who are more likely to cognitively de-
cline, there is a greater change for the treatments to resist, and an
expected gain in power. Structural MRI measures, for instance, are
useful not only for measuring brain atrophy (Frisoni et al., 2010;
Hua et al., 2011; Leow et al., 2006; McEvoy et al., 2010) but also for
predicting brain atrophy, which can be used to pre-select subjects
who will decline in a clinical trial (Lorenzi et al., 2010; McEvoy et
al., 2010). PET scanning with FDG or PiB, cerebrospinal ﬂuid (CSF)
measures of Abeta42, tau and phosphorylated tau, as well as
genotyping for the Apolipoprotein E (ApoE) ε4 allele (ApoE4) have
also been proposed to pre-select people for clinical trials, reducing
sample size requirements (Lorenzi et al., 2010; McEvoy et al., 2010).
Multivariate methods can also combine multiple biomarkers to select
subjects more likely to show detectable change in hypothetical AD
trials (Kohannim et al., 2010).cense.
Table 1
Number of subjects, distribution of sex and age (mean ± SD years), number of carriers
(C) and non-carriers (NC) for the ApoE4 risk allele, and distribution of alleles for CLU
(rs11136000), PICALM (rs3851179) and CR1 (rs3818361) AD risk-conferring polymor-
phisms are displayed for subjects with Alzheimer's disease (AD), mild cognitive im-
pairment (MCI), healthy controls (CTL), and also for all 500 ADNI subjects combined.
These 500 subjects were studied, as they had available 24-month as well as baseline
MRI scans. Minor allele frequencies (MAFs) and Hardy–Weinberg Equilibrium (HWE)
p-values for the candidate variants are also shown in the last column. The risk allele
for CR1 is the minor allele (i.e., T), but the risk alleles for CLU and PICALM are the
major alleles (i.e., C and G, respectively).
AD MCI CTL All MAF/HWE p
N 106 234 160 500
Age 75.5 ± 7.4 74.9 ± 6.9 76.3 ± 4.9 75.5 ± 6.5
Sex 50 F 79 F 75 F 204 M
56 M 155 M 85 M 296 F
ApoE4 73 C 128 C 45 C 246 C
33 NC 106 NC 115 NC 254 NC
CLU 36 C/C 95 C/C 61 C/C 192 C/C 0.38/0.84
54 C/T 104 C/T 76 C/T 234 C/T
16 T/T 35 T/T 23 T/T 74 T/T
PICALM 44 G/G 102 G/G 58 G/G 204 G/G 0.36/0.69
50 G/A 102 G/A 82 G/A 234 G/A
12 A/A 30 A/A 20 A/A 62 A/A
CR1 64 C/C 153 C/C 119 C/C 336 C/C 0.18/0.76
38 C/T 72 C/T 39 C/T 149 C/T
4 T/T 9 T/T 2 T/T 15 T/T
The allele frequency distributions between AD, MCI, and CTL did not show any statisti-
cally signiﬁcant differences in CLU (χ2 = 1.55, p = 0.82), PICALM (χ2 = 2.60, p =
0.63), or CR1 (χ2 = 7.43, p = 0.11).
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(Bertram et al., 2007) and ApoE genotyping has already been studied
for pre-selecting individuals for potential AD trial enrichment (Beckett
et al., 2010; Kohannim et al., 2010; McEvoy et al., 2010; Nestor et al.,
2008; Risacher et al., 2010). Carriers of at least one copy of the ApoE4
variant make up ~20% of the normal elderly population (e.g., Crivello
et al., 2010), and each E4 allele carried roughly triples a person's lifetime
risk of developing AD. Even so, ApoE does not account for all of the
inherited risk for AD. As other risk genes are discovered and validated,
genotyping should even further reduce sample size requirements.
Two recent genome-wide association (GWA) studies recently implicat-
ed several highly prevalent genetic variants in the clusterin (CLU),
phosphatidylinositol binding clathrin assembly protein (PICALM) and
the complement component receptor 1 (CR1) genes, beyond the well-
known ApoE gene; carriers of risk-conferring variants in any of these
genes have an additional 10–20% increased risk for Alzheimer's disease,
if other risk factors are equal (CLU and CR1; Lambert et al., 2009, CLU and
PICALM; Harold et al., 2009). Since then, several studies, includingmeta-
analyses, have replicated these ﬁndings in large cohorts of healthy con-
trols and pathologically conﬁrmed, late-onset AD patients (Carrasquillo
et al., 2010; Corneveaux et al., 2010; Jun et al., 2010). Most recently,
Ferrari et al. (2012) also veriﬁed the associations of these genetic vari-
ants with AD by sequencing the respective genes' coding regions.
Though the precise role of these speciﬁc variants remains unknown,
there are several links between the protein products of CLU, PICALM,
and CR1 and AD pathogenesis: CLU with beta-amyloid aggregation,
deposition, and clearance, PICALM with synaptic function, clathrin-
mediated endocytosis, and amyloid precursor protein recycling, and
CR1with inﬂammation and complement-mediated beta-amyloid clear-
ance (Holton et al., 2013; Jun et al., 2010; Sleegers et al., 2010).
Here, we assessed how the 3 recently discovered AD risk genes
(i.e., PICALM, CLU and CR1), along with ApoE, combine to affect
brain tissue loss rates in Alzheimer's Disease Neuroimaging Initiative
(ADNI) subjects. We hypothesized that a genetic score derived from
these top AD risk genes would enrich a hypothetical 2-year clinical
trial beyond just selecting ApoE4 carriers. We focused on MCI and
healthy controls, similarly to prior enrichment studies (Lorenzi
et al., 2010; McEvoy et al., 2010), mainly due to the crucial need for
early interventions in AD (Kozauer and Katz, 2013).
2. Methods
2.1. Subjects
Subjects considered for this study were participants in the ﬁrst
phase of the ADNI project, also known as “ADNI1” (Weiner et al.,
2012). ADNI was launched as a public–private partnership in 2004
by the NIH, private pharmaceutical companies, and non-proﬁt organi-
zations, The goal of ADNI is to determine biological markers of
Alzheimer's disease through neuroimaging, genetics, neuropsycho-
logical tests and other measures, to develop and monitor new thera-
pies, and reduce the time of clinical trials. Subjects were recruited
from 58 sites across North America. The study was conducted
according to the Good Clinical Practice guidelines, the Declaration of
Helsinki, and U.S. 21 CFR Part 50—Protection of Human Subjects,
and Part 56—Institutional Review Boards. Written informed consent
was obtained from all participants before protocols were performed.
All data acquired as part of this study are publicly available (http://
adni.loni.ucla.edu/).
All ADNI subjects underwent thorough clinical and cognitive as-
sessment at the time of scan acquisition to establish diagnosis. In
this study, all subjects with both baseline 1.5-Tesla scans and longitu-
dinal follow-up scans at 24 months were assessed. The 24-month
follow-up was picked, as 2 years is a fairly typical duration for an
MCI or AD clinical trial. All subjects with available 24-month scans
and genotypes were included. The mini-mental state exam (MMSE)was administered to provide a global measure of mental status
(Cockrell and Folstein, 1988). The Clinical Dementia Rating (CDR)
was used to assess dementia severity (Morris, 1993). Healthy volun-
teer status was determined if a subject had MMSE scores between
24 and 30 (inclusive), a CDR of 0, and was non-depressed, non-MCI,
and non-demented. Mild cognitive impairment (MCI) diagnosis
was determined if a subject had MMSE scores between 24 and 30
(inclusive), a memory complaint, objective memory loss measured
by education adjusted scores on the Wechsler Memory Scale Logical
Memory II, a CDR of 0.5, absence of signiﬁcant levels of impairment
in other cognitive domains, essentially preserved activities of daily
living, and an absence of dementia. AD was diagnosed based on the
National Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer's Disease and Related Disorders Association
(NINCDS–ADRDA) criteria for probable AD (McKhann et al., 1984),
MMSE scores between 20 and 26 (inclusive), and CDR of 0.5 or 1.0.
Deﬁnitive autopsy-based diagnosis of AD was not possible.
Here, we studied 500 ADNI subjects (mean age of 75.5 ± 6.5 SD;
296 males and 204 females; see Table 1 for full demographics) with
available genotypes and scans at baseline and 24 months after diag-
nosis. All subjects are Caucasian, identiﬁed by self-report, and con-
ﬁrmed with multi-dimensional scaling analysis (Stein et al., 2010).
2.2. Imaging
MRI scans of the brainwere obtained fromADNI subjectswith a stan-
dard 1.5 T protocol. A sagittal 3DMP-RAGE sequence was used, that had
been optimized for consistency across sites (Jack et al., 2008; Leow et al.,
2006; TR/TE = 2400/1000 ms; ﬂip angle = 8°; FOV = 24 cm; ﬁnal
reconstructed voxel resolution = 0.9375 × 0.9375 × 1.2 mm3). Scans
at 12 and 24 months were linearly registered to baseline scans and
aligned to a template after standard corrections, which include
Gradwarp (Jovicich et al., 2006), B1-correction (Jack et al., 2008), bias
ﬁeld correction (Sled et al., 1998), and phantom-based geometrical scal-
ing (Gunter et al., 2006). Masks excluding non-brain tissues were
obtained using a robust brain extraction tool (ROBEX; Iglesias et al.,
2011). A bias-free tensor-based morphometry analysis (TBM; Hua
et al., 2013; Leow et al., 2006) was used based on a non-linear inverse
Fig. 1. Sample size estimates (n80) are shown for a hypothetical clinical trial with a
mixture of healthy control and mild cognitive impairment (MCI) subjects (in the pro-
portions enrolled by ADNI), as a function of number of subjects (N) after ranking sub-
jects according to a cumulative genetic risk score derived from ApoE4 (coded as 0 or 1
for carrier status) and single nucleotide polymorphisms in CLU, CR1 and PICALM (blue).
The breakpoints represent different risk score values, as these are not continuous (see
Inline Supplementary Table S1 for a list of risk scores and corresponding allele combi-
nations). Permutations are performed by randomizing the ranking procedure 1000
times and calculating n80 estimates for each N (all permuted estimates are shown in
black). ApoE4 reduces n80s from 142 to 94, based on data from a subset of 173 subjects
(44% of all MCI and controls). Using the cumulative genetic risk score, this is further re-
duced to 69 when pre-selecting the top ~15%, and 60 when pre-selecting the top ~10%
of the subjects.
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scans identically, and symmetrically (Leow et al., 2005). In voxelwise
analysis, the volumetric change over time (over a 2-year follow-up)
was regressed against the joint effect of genetic variants at each voxel,
using multiple linear regression. Correction for multiple spatial compar-
isons was performed with a regional false discovery rate (FDR) method
(Langers et al., 2007). In power analyses, a 2-year atrophy rate was com-
puted from a statistically deﬁned region-of-interest to summarize tem-
poral lobe atrophy (Hua et al., 2011).
2.3. Genetic risk score calculation
The ADNI genotyping procedures are thoroughly described in
Saykin et al. (2010). For this study, a genetic risk score was calculated
from previously identiﬁed and replicated top SNPs in CLU
(rs11136000), PICALM (rs3851179) and CR1 (rs3818361) using a lin-
ear model of aggregate disease risk, with weights for each variant
equal to the logarithm of odds ratios reported in a recent meta-
analysis by Jun et al. (2010), which is in agreement with odds ratios
reported in other studies (Harold et al., 2009; Lambert et al., 2009).
Odds ratios for the minor alleles of CLU, PICALM, and CR1 were there-
fore set to 0.9, 0.9 and 1.1, respectively. The odds ratio for carrying
ApoE4 was set to 3. This is an underestimation as odds ratios are
higher in ApoE e4/e4 subjects (Farrer et al., 1997) who are also in-
cluded here, but any larger value would yield the same ranking of
subjects as the effect of ApoE4 overrides that of all other candidate
SNPs (in other words the score assigned to ApoE4 is so large that
the exact value of the score does not affect the eventual ranking).
The score calculation and ranking procedure is further detailed in
the Supplementary material and Inline Supplementary Table S1.
Inline Supplementary Table S1 can be found online at http://dx.
doi.org/10.1016/j.nicl.2013.05.007.
In voxelwise analysis, multiple linear regression was used to predict
volumetric differences at each voxel based on candidate genotypes,
after adjusting for covariates (sex, age, and population structure param-
eters derived from multi-dimensional scaling analysis (MDS) as de-
tailed in Hibar et al., 2011; Stein et al., 2010). This multiple regression
analysis was more stable than regressing the same aggregate risk
score against the signal at each voxel, as the variants' odds ratios from
case–control studies may not necessarily correspond to the appropriate
weights for predicting volume differences at each voxel.
2.4. Power analysis
As in prior studies (Hua et al., 2011; Kohannim et al., 2010), sam-
ple size estimates were calculated according to the following formula:
n ¼
2σ2 z1−α=2 þ zpower
 2
0:25βð Þ2 :
Here σ and β denote the mean and standard deviation of the atro-
phy rates respectively, α is set to be nominal 0.05, and the desired
power is 80%. Subjects were ranked according to their composite ge-
netic score to determine how much the sample size estimates would
be reduced if the study was restricted to those with higher-risk
scores. The ranking procedure was randomized 1000 times to com-
pare observed power results with those obtainable by chance, i.e.,
when just selecting subsets of people from the overall sample with-
out regard to their genotypes.
3. Results
We ﬁrst studied the sample size enrichment effect using genotype
scores for a mixed group of MCI and cognitively healthy control sub-
jects, in the proportions they were enrolled in ADNI (i.e., roughly 2MCI subjects for each healthy control subject). We ranked the 394
subjects by their cumulative risk score based on ApoE4 carrier status
and their CLU, CR1 and PICALM genotypes. We related our risk ranking
to the sample size for a potential clinical trial needed to detect a 25%
reduction in atrophy rates within two years with 80% power. The
temporal lobe atrophy rate we used for our sample size calculations
was signiﬁcantly correlated with 2-year change in sum-of-boxes Clin-
ical Dementia Rating (CDR-SOB) scores (R2 = 0.25, p b 2 × 10−16;
see Inline Supplementary Fig. S1 for details). We observed boosting
of trial power by selecting those at greater genetic risk (Fig. 1). Sam-
ple size estimates for a trial evaluating temporal lobe atrophy were
reduced from 142 to 94 by selecting ApoE4 carriers, and to even
smaller estimates in subjects with more risk alleles (69 when
selecting only the top ~15% of the subjects, and 60 when selecting
only the top ~10% of the subjects who had the greatest aggregate
risk). These cutoffs correspond to risk scores of 1.08 and 1.10, respec-
tively (see Inline Supplementary Table S1). We ensured this was not
due to chance through 1000 permutations: all subjects were ranked
randomly and sample size estimates were computed for random sub-
sets (Fig. 1). When we coded ApoE as 0, 1 or 2 for the number of ε4
alleles (instead of 0 for carrying no copies of ε4 and 1 for carrying
any number of copies of ε4), boosting was still observed in a similar
way (Inline Supplementary Fig. S2).
Inline Supplementary Figs. S1 and S2 can be found online at http://
dx.doi.org/10.1016/j.nicl.2013.05.007.
Next, we tested whether the boosting of trial power also applies to
MCI subjects and cognitively healthy controls, when considered sep-
arately. Reduced sample sizes were observed in MCI subjects and
were consistently lower than permuted estimates (Fig. 2A). In car-
riers of at least one copy of the risk allele, ApoE4, the sample size es-
timate was reduced to 67 (from 105 when considering all MCI
subjects). Selecting the top ~20% and ~10% of high-risk MCI subjects
yielded estimates of 58 and 50, respectively. These cut-offs corre-
spond to the same risk score thresholds as those considered above,
which led to reduced estimates of 69 and 60. In cognitively healthy
Fig. 2. Sample size estimates (n80) are shown for hypothetical clinical trials as a func-
tion of number of subjects (N) after ranking subjects according to a cumulative genetic
risk score derived from ApoE4 (coded as 0 or 1 for carrier status) and single nucleotide
polymorphisms in CLU, CR1 and PICALM (blue). The breakpoints represent different risk
score values, as these are not continuous (see Inline Supplementary Table S1 for a list
of risk scores and corresponding allele combinations). Permutations are performed by
randomizing the ranking procedure 1000 times and calculating n80 estimates for each
N (all permuted estimates are shown in black). Panel A shows results for MCI subjects.
Selection of subjects who carry at least one copy of the risk allele, ApoE4 (~55% of all
MCI subjects), reduces n80s from 105 to 67. This is further reduced from the remaining
three risk variants to 58 in the top ~20% and to 50 in the top ~10% of MCI subjects, re-
spectively. Permutations consistently provide worse estimates. Panel B displays similar
results for cognitively healthy subjects only. Selecting ApoE4 carriers (28% of all con-
trols) reduces n80 minimally from 120 to 117. Selecting the top ~10% of control sub-
jects with highest genetic risk reduces n80 to 55, still falling short of signiﬁcance
when compared to random permutations (p ~ 0.11).
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genetic risk scores was not observed (Fig. 2B). Selection of ApoE4
carriers reduced the sample size estimate only from 120 to 117,
which was not signiﬁcant. Selecting the top ~10% of control subjects
with highest genetic risk reduces this further to 55, but this reduction
still fell short of signiﬁcance when compared to permutations
(p ~ 0.11).
We then sought to statistically explore how much CLU, PICALM,
and CR1 contribute to the reduction in sample size, independently
of ApoE. We performed 1000 permutations as above, but instead
started with ApoE carriers and permuted within this subgroup
only to see if further n80 reductions from the aggregate genotype
risk score were statistically signiﬁcant. In the mixture of MCI andcognitively normal ApoE carriers, boosting of n80 from 94 to 69 by
selecting the subjects with risk scores above 1.08 (top ~15% in
above analysis) was statistically signiﬁcant (p = 0.035). Selecting
those with scores above 1.10 (top ~10% above), which reduced n80
from 94 to 60 was suggestive, but did not reach signiﬁcance (p =
0.070). When we considered MCI ApoE carriers alone, neither reduc-
tions from 67 to 58 and 50 were statistically signiﬁcant (p = 0.20,
and p = 0.14, respectively).
Although we were mostly interested in MCI and healthy control
subjects due to the importance of early intervention in clinical trials,
we also investigated a similar enrichment strategy within the whole
cohort of 500 subjects, including those with AD. Similar results were
obtained with the inclusion of AD subjects. Selecting the subset of
246 ApoE carriers reduced the sample size from 135 to 84. The sample
sizes were further reduced to 65 and 59 by selecting subsets of
subjects with high genetic risk scores with the same two score
breakpoints used above. Permutations conﬁrmed statistical signiﬁ-
cance. Boosting in the full cohort – and corresponding permutation
results – are shown in Inline Supplementary Fig. S3.
Inline Supplementary Fig. S3 can be found online at http://dx.doi.
org/10.1016/j.nicl.2013.05.007.
When regressed against the 24-month atrophy rate based on the
temporal lobe statistical ROI in all 500 ADNI subjects, our 4-gene
risk score was statistically signiﬁcant in the expected direction
(β = −1.43; p b 2 × 10−16) after adjusting for age, sex, and pop-
ulation structure. When ApoE was not included in the score, but in-
cluded as a covariate instead, the 3-gene risk score association was
still in the expected direction, but no longer statistically signiﬁcant
(β = −1.17; p = 0.11). In a post-hoc analysis, we assessed whether
there were regions in our voxelwise atrophy maps where the
3-gene association was statistically signiﬁcant. The cumulative effect
of CLU, CR1 and PICALM SNPs was regressed against voxelwise mea-
sures of volumetric change over 2 years in maps of the temporal
lobes. As explained in the Methods section, we used multiple linear
regression with the 3 SNPs as predictors here, instead of a score
based on the case–control odds ratios, which do not necessarily re-
ﬂect the effect of each SNP on structural brain atrophy at each
voxel. After adjusting for ApoE status and other covariates (i.e., sex,
age and population structure) and correcting for multiple compari-
sons across voxels, we found statistically signiﬁcant spatial effects in
the temporal lobes for 500 subjects with the rate of volumetric
brain change 24 months after the ﬁrst scan, mostly in the entorhinal
cortex and hippocampus (Fig. 3). In a separate analysis, we also
added diagnostic status (AD, MCI, or control) as another covariate,
and obtained similar, in fact stronger, results (Fig. 4).
4. Discussion
In this study, we showed that an aggregate genotype risk score de-
rived from variants in the CLU, PICALM and CR1 risk genes for
Alzheimer's disease can be used to enrich a hypothetical clinical
trial through genetic proﬁling. Prior studies show successful enrich-
ment of AD and MCI trials with ApoE4 genotyping (Kohannim et al.,
2010; McEvoy et al., 2010) and ApoE's signiﬁcant effect on brain atro-
phy, independently of clinical diagnosis (Potkin et al., 2009). To our
knowledge, no previous study has investigated whether we can fur-
ther reduce sample sizes by including more risk variants to select
the sample.
We ﬁrst showed that selecting subjects who carry at least one
copy of ApoE4 reduced the sample size required to detect an 80% at-
rophy rate in 2 years by about 34% in a group of MCI and healthy con-
trol subjects and 36% in MCI subjects only. This reduction is consistent
with McEvoy et al.'s (2010) reported 10–43% reduction in sample size
requirements when using ApoE4 to pre-select a sample. Enrichment
was not explored for cognitively healthy controls in the McEvoy
study, but we did not ﬁnd a signiﬁcant sample size reduction for
Fig. 3. Single nucleotide polymorphisms in CLU, PICALM and CR1 are jointly regressed against voxelwise, 3D maps of 24-month temporal lobe atrophy in 500 ADNI subjects with
available scans. Sex, age, ApoE status and population structure are adjusted for in each regression. Multiple comparisons across voxels are corrected with a regional FDR method;
only voxels that survive this statistical correction are shown in color. Representative axial and sagittal slices are shown, which show the statistically signiﬁcant additive, bilateral
and rather symmetric effects of the variants in the hippocampus and entorhinal cortex. Warmer colors represent more signiﬁcant effects. Images are in radiological convention. A
total of 15,711 voxels survive the p b 0.05 threshold with a pmin of 1.04 × 10−4. The regional (searchlight) FDR technique renders 3130 voxels signiﬁcant (i.e., with corrected
p-values below 0.05).
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maps show a low-grade and diffuse pattern of atrophy in cognitively
healthy controls, whereas effects are stronger and more concentrated
in regions such as the temporal lobes in AD and MCI subjects. Prior
studies have uncovered signiﬁcant differences in structural and func-
tional imaging measures such as cortical thickness (Burggren et al.,
2008) and beta amyloid (Morris et al., 2010) in cognitively healthy
ApoE carriers, but the effects are either absent in classic AD brain
areas such as the hippocampus, or they appear to be diffuse across
several brain regions. Numerical summaries designed to capture lo-
calized atrophy in the classic AD brain areas (trained by AD subject
scans) may, therefore, not work well to capture atrophy in healthy
aging subjects (Hua et al., 2013).
In our study, selecting subjects who, in addition to carrying ApoE4,
carried high-risk combinations of the CLU, CR1 and PICALM polymor-
phisms led to an additional reduction of 51–58% in sample size in a
mixed group of MCI and controls and 45–52% in MCI subjects only.
These were statistically signiﬁcant when compared to a randomized
subject selection procedure, though when considered strictly inde-
pendently from ApoE, statistical signiﬁcance was limited to the
mixed group of MCI and controls with the 51% reduction. In cogni-
tively healthy controls, a 56% reduction was observed through
selecting the top 10% of high-risk subjects, but did not reach signiﬁ-
cance. A simple explanation may be that we need larger sample
sizes for the healthy controls to demonstrate signiﬁcant boosting of
trial power, whereas we have fewer control subjects than MCI in
our study. However, the discrepancy between the ﬁndings in the
two diagnostic subgroups may also suggest that clinical trials might
beneﬁt from either including MCI subjects only, or enrolling aFig. 4. Single nucleotide polymorphisms in CLU, PICALM and CR1 are jointly regressed again
available scans. Diagnostic status (i.e., either AD, MCI, or control) in addition to sex, age, A
across voxels are corrected with a regional FDR method; only voxels that survive this statis
as in Fig. 3, indicating the statistically signiﬁcant additive effects of the variants in the hippo
ages are in radiological convention. A total of 23,202 voxels survive the p b 0.05 threshold
threshold of 0.05 with the regional (searchlight) FDR technique.mixture of MCI and healthy controls (i.e., enrollment regardless of
clinical diagnosis) who instead have higher genetic risk scores. En-
rolling MCI subjects for AD trials is not without its limitations, as
criteria for MCI may lead to missing AD converters or including con-
trols (Visser et al., 2005). Nonetheless, this very limitation may be al-
leviated by further excluding subjects with lower genetic risk. In
ADNI, as in most other neuroimaging studies, autopsy conﬁrmation
of AD diagnosis was not possible, and at least in principle, CSF bio-
markers (for tau protein, etc.) could have been used to corroborate
the clinical diagnosis, which was made according to the NINCDS–
ADRDA criteria. CSF measures of Tau, P-Tau, and A-beta are available
for only a subset of the ADNI subjects who have longitudinal data, so
we did not use them here to further inform the diagnosis. Also, it
must be conceded that some MCI participants might harbor AD pa-
thology and might be considered as having AD in its initial stages.
We further reported regionally signiﬁcant aggregate effects of CLU,
PICALM and CR1 variants on TBM-derived three-dimensional maps of
temporal lobe atrophy. The use of a cumulative genetic risk score has
substantial practical consequences, beyond the standard practice of
focusing on ApoE as the dominant risk gene for late-onset AD. The 3
more recently discovered AD risk genes have been previously associ-
ated with quantitative, neuroimaging summary measures (reviewed
in Braskie et al., 2011a) in addition to their high degree of replication
as AD risk genes in case–control studies (Carrasquillo et al., 2010;
Ferrari et al., 2012; Harold et al., 2009; Jun et al., 2010; Lambert et
al., 2009). Signiﬁcant association of PICALM with MRI-derived hippo-
campal volume and entorhinal cortex thickness, and that of CR1 on
entorhinal cortex thickness have been recently reported (Bifﬁ et al.,
2010). Another study found an association of CR1 with entorhinalst voxelwise, 3D maps of 24-month temporal lobe atrophy in 500 ADNI subjects with
poE and population structure is adjusted for in each regression. Multiple comparisons
tical correction are shown in color. Representative axial and sagittal slices are shown,
campus and entorhinal cortex. Warmer colors represent ‘more signiﬁcant’ effects. Im-
with a pmin of 2.51 × 10−5. A subtotal of 6114 voxels survive the corrected p-value
832 O. Kohannim et al. / NeuroImage: Clinical 2 (2013) 827–835cortex volume in young, healthy adults (Bralten et al., 2011). Al-
though the association of our 3-SNP risk score with the average atro-
phy rate across the temporal lobe fell short of signiﬁcance, our results
provide a voxelwise complement to these studies, as we found spa-
tially signiﬁcant effects in temporal lobe regions that are in agree-
ment with their ﬁndings. The rs11136000 variant in CLU, though
not signiﬁcant in Bifﬁ et al.'s study, has been associated with micro-
structural white matter integrity using diffusion tensor imaging in
young, healthy adults (Braskie et al., 2011b). Although the ADNI co-
hort was included in the Jun et al. (2010) meta-analysis, the three
SNPs have been discovered and replicated in multiple, large cohorts
that do not overlap with ADNI and there is, therefore, no circularity
in our genetic results; in other words, the SNPs chosen were based
on their association with AD in many other samples, and not because
they were associated with brain atrophy in the ADNI dataset
speciﬁcally.
The outcome measure we implemented here for performing our
power analyses was based on numerical summaries of temporal
lobe atrophy derived from tensor-based morphometry of MRI scans
(Leow et al., 2006). Neuroimaging measures can boost power for clin-
ical trials (Leung et al., 2010; McEvoy et al., 2010; Nestor et al., 2008;
Risacher et al., 2010). As detailed in Hua et al. (2009), we used a sta-
tistically deﬁned region-of-interest in the temporal lobes, which can
be a more powerful outcome measure for tracking atrophy than a
standard voxelwise average. This region-of-interest was obtained
from a training set of 20 AD subjects. Since our enrichment analyses
focused on MCI and control subjects, overﬁtting due to training and
testing with overlapping subjects was avoided. Despite the use of a
sophisticated imaging-based outcome measure, we demonstrate its
correlation with clinical dementia scores, and expect that our ﬁndings
with respect to sample size reduction using multiple AD risk genes
should generalize to trials with purely clinical outcome measures as
well, as these are top SNPs from case–control genome-wide associa-
tion studies (Harold et al., 2009; Lambert et al., 2009).
A genotype-based enrichment approach may offer several poten-
tial advantages for AD drug trials. As discussed in Schork and Topol
(2010), trials for both prevention and therapy of disease may beneﬁt
from such enrichment. For prevention, subjects with high-risk geno-
types (e.g., ApoE4 carriers with multiple CLU, PICALM and CR1 risk al-
leles in our study) may be more likely to respond to a preventive
agent, thereby making trials more cost-effective and efﬁcient. The
presence of subjects in a trial who are unlikely to decline at all
makes it difﬁcult to pick up drug effects. Though our multilocus en-
richment approach is related to that of other AD enrichment studies,
where neuroimaging and cerebrospinal ﬂuid biomarkers are shown
to help select at-risk subjects, it is particularly helpful as it may be
less costly and can be obtained from subjects quickly and efﬁciently,
and potentially avoid issues such as patients' willingness to undergo
MRI or a lumbar puncture. Although several of the sample size reduc-
tions we obtained from our candidate genes were not signiﬁcant after
adjustment for ApoE alone, the general risk score approach, perhaps
ﬁne-tuned with additional genes and larger numbers of subjects,
has the potential to offer such advantages.
A genotype proﬁling enrichment strategy is also promising for
therapeutic trials, as risk genes often reﬂect molecular mechanisms
of disease and, arguably, may affect subjects' degree of responsive-
ness to speciﬁc therapeutics. The protein products of CLU, CR1, and
PICALM are linked to inﬂammatory, amyloid, lipid and chaperone
pathways that are implicated in neurodegeneration (Sleegers et al.,
2010). Genetic proﬁling based on these candidate genes may
help with AD trial enrichment. This overall approach is related to
pharmacogenetic sampling (i.e., selecting genetic subgroups of pa-
tients who are more likely to respond to treatment; Schork and
Topol, 2010). However, the main premise is to avoid sampling people
who will not decline during the trial, and preferentially sample those
who will. This sampling may also be performed early, which may helpin cases where therapeutics work better in the earlier stages of a dis-
ease. Such pharmacogenetic designs have already been explored with
ApoE in the context of AD trials (Roses, 2009; Zamani et al., 2011) and
hinted at in mouse model studies (Cramer et al., 2012).
Designing clinical trials based on genotypes also has some chal-
lenges and limitations. Screening out subjects with certain genotypes
may even miss trial effects, particularly if it is uncertain how the risk
gene affects responses to therapeutic agent. In theory at least, people
at low genetic risk may respond better to a treatment; regardless of
this, however, their response may be extremely challenging to detect
if they decline less than others, when not treated. Similarly, our study
is limited to four AD risk genes. The three candidate SNPs we included
in addition to ApoE are top GWAS ﬁndings, with recent replications in
very large cohorts (see Introduction). There are, however, other AD
risk variants that might potentially be included in a risk score for
trial enrichment, particularly once they are further validated. Genetic
variants in BIN1 (Kingwell, 2013; Lambert et al., 2011) and those in
ABCA7, EPHA1, CD33, CD2AP, and MS4A6A/MS4A4E (Hollingworth et
al., 2011), for instance, were recently discovered in large AD GWAS
studies, some of which may have roles in AD pathogenesis (Holton
et al., 2013). Genetic variants in TOMM40 have also been linked to
AD (Roses et al., 2010), though the proximity and linkage disequilibri-
um between this gene and ApoE led to recent investigations that failed
to replicate this association and cast doubt on ApoE-independent risk
signals in the chromosomal region (Cruchaga et al., 2011; Jun et al.,
2012). In practice, our approach may be too selective for a clinical
trial, but nonetheless serves as a proof-of-principle study to demon-
strate enrichment using multiple genotypes.
Another limitation of our study is that we did not include gene–
gene interactions in our model. As the ﬁrst paper to consider genes
beyond ApoE for clinical trial enrichment, we started with a linear,
additive model, modeling SNP effects based on well-recognized,
GWAS-validated odds ratios. Some interactions between our candi-
date genes, particularly those between PICALM and ApoE have been
reported in prior work (Jun et al., 2010). However, they have not al-
ways been replicated. The ﬁrst GWAS that identiﬁed PICALM in AD
(Harold et al., 2009), in fact, failed to ﬁnd such interaction, making ef-
fect size estimation for interaction terms more complex. In addition,
we may be underpowered to pick up interaction effects, as they as-
sume a main effect is present, and that modulatory effects on the
main effect can be detected. Truly vast samples, as well as novel com-
putational strategies, may be needed to detect interactions among all
pairs of N SNPs. One effort in this regard is Hibar et al. (2013). Envi-
ronmental factors may also modify genetic susceptibility in the con-
text of complex traits and disorders (De Jager et al., 2009; Morrison
et al., 2007; Qi et al., 2012). Nonetheless, the general approach pro-
posed here could also be extended to include any known environ-
mental risk factors that might modulate disease risk (such as
educational level, exercise, and alcohol intake).
Allele frequencies in the general population may also raise some
practical issues for implementing this approach. In our sample, the
risk alleles for PICALM and CLU are relatively common (major allele fre-
quencies of 0.74 and 0.72, respectively), but that of CR1 is lower (minor
allele frequency of 0.18). Some studies report a higher MAF of 0.26 for
the CR1 SNP (Jun et al., 2010), but our MAF estimate is consistent with
those reported in initial GWAS studies in Caucasian subjects (Lambert
et al., 2009). Uncommon genotypesmay cause a trial to bemore expen-
sive if a large number of subjects need to be screened (Schork and
Topol, 2010). The cost/beneﬁt depends on the cost of screening proce-
dures relative to neuroimaging and longitudinal assessment, which
may be much greater. In addition, pharmacogenomic proﬁling intro-
duces ethical dilemmas, which complicate its application to drug trials;
speciﬁcally some people may not have access to a new treatment as
quickly as others, if genetic tests are among the criteria required to ob-
tain it (Issa, 2002). Nevertheless, as risks and beneﬁts of using a
multilocus genetic proﬁling are weighed for speciﬁc trials and more is
833O. Kohannim et al. / NeuroImage: Clinical 2 (2013) 827–835understood about our candidate risk genes and their roles in AD pathol-
ogy, our results may have important implications for the design of AD
clinical trials. At the very least, genotyping could be done retrospective-
ly, to see if effects would have been more powerful if obtained from a
pre-selected sample.Acknowledgments
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